Treatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children. Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes. The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies. These targeted therapies include enzyme replacement therapies, gene therapies targeting the brain and the eye, cell therapies, and pharmacological drugs that could modulate defective molecular pathways. Such therapeutic developments have the potential to enable earlier diagnosis and better targeted therapeutic management. The first approved treatment is an intracerebroventricularly administered enzyme for neuronal ceroid lipofuscinosis type 2 disease that delays symptom progression. Efforts are underway to make similar progress for other forms of the disorder.

Table of contentsO1 The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D)Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Deborah Marshall, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà Morales, Keith Tolley, Mondher Toumi, Harry TelserO2 Newborn Screening: the potential and the challengesJames R BonhamO3 Untreatable disease outcomes - how would we measure them?Helmut Hintner, Anja Diem, Martin LaimerO4 Taking Integrated Care Forward: Experiences from Canada to inspire service provision for people living with rare disease in EuropeRéjean HébertO5 Listening to the patient’s voice: social media listening for safety and benefits in rare diseasesNabarun Dasgupta, Carrie E. Pierce, Melissa JordanO6 Via Opta: Mobile apps making visually impaired patients’ lives easier Barbara Bori, Mohanad Fors, Emilie PrazakovaO7 A report of the IRDiRC “Small Population Clinical Trial” Task ForceSimon DayO8 HAE patient identification and diagnosis: An innovative, ‘game changing’ collaborationThomas J. Croce Jr.O9 Co-creating with the community: primary packaging & administration for people with haemophiliaJonas Fransson, Philip WoodO10 Go with Gaucher, taking forward the next generation. How to involve young people to create a new generation of patient advocatesAnne-Grethe Lauridsen, Joanne Higgs, Vesna Stojmirova AleksovskaP1 ODAK – Orphan Drug for Acanthamoeba KeratitisChristina Olsen, Ritchie Head, Antonio Asero, Vincenzo Papa, Christa van Kan, Loic Favennec, Silvana Venturella, Michela Salvador, Alan KrolP5 Rare Navigators help people living with rare diseases to manage the social – and healthcare systems Stephanie J. Nielsen, Birthe B. HolmP6 The eAcademy for Tay-Sachs & Sandhoff disease appDaniel Lewi, Patricia DurãoP10 The role of a patient organisation in driving the research agenda in a rare diseaseHeather Band, Andrea WestP13 Expertise for rare diseases mappedMarinda J.A. Hammann, Marije C. Effing-Boele, Hanka K. DekkerP14 The hidden costs of rare diseases: a feasibility studyAmy Hunter, Amy SimpsonP15 FDA’s new natural history grant program: support to build a solid foundation for development of products for rare diseasesGumei Liu, Katherine Needleman, Debra Lewis, Gayatri RaoP17 Understanding the wider impact of adrenal insufficiency: patient organisation involvement in the TAIN projectAmy Simpson, Amy Hunter, Martin J WhitakerP20 Bridging the gaps between medical and social care for people living with a rare diseaseRaquel Castro

No abstract